Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd. (DRTS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · DRTS · as of Jun 9, 2026
Key Statistics
Explore Alpha Tau Medical Ltd. Data
drts stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 6 · Buy rate: 83.3%
The DRTS analyst consensus is Buy, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $13.33, representing +43.64% upside from the current price of $9.28.
Competitors & Peers
drts competitorsDRTS
ACIU
ALDX
AMRN
ANRO
CADLStock Performance
Full HistoryAbout Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd. is a clinical-stage biotechnology company dedicated to the advancement and eventual commercialization of innovative cancer treatments. Their primary focus is on "Alpha DaRT" (Di…
what is alpha tau medical ltd. · drts stock overview · alpha tau medical ltd. company profile · who is alpha tau medical ltd. ceo · drts NASDAQ · alpha tau medical ltd. headquarters · alpha tau medical ltd. business segments
About Stock Overview & Key Data
Alpha Tau Medical Ltd. (DRTS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 8, 2021. As of the latest trading session, DRTS stock price is $9.28, with a market capitalization of $838.2M. The stock has returned +196.49% over the past 12 months and +87.47% year-to-date.
According to 6 Wall Street analysts, the consensus rating for Alpha Tau Medical Ltd. stock is Buy, with an average 12-month price target of $13.33. In fiscal year 2025, Alpha Tau Medical Ltd. reported revenue of — and net income of -$42.6M. For detailed data — including Alpha Tau Medical Ltd. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Alpha Tau Medical Ltd. (DRTS) stock price is $9.28. The stock is traded on NASDAQ under the ticker symbol DRTS. The 52-week range is $2.85 – $11.62.